| Name | Title | Contact Details |
|---|
Greenwich Biosciences is the leader in researching cannabinoid medicines for rare epilepsies like Dravet Syndrome, LGS, TSC, and others.
Pharmaprint Inc is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 1993, BTL has grown to become one of the world’s major manufacturers of medical equipment. BTLs major segments include physical therapy, cardiology and medical aesthetics.
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.